Abstract
Recent reports have described a new strategy for differentiation and maturation of monocyte (Mo)-derived dendritic cells (DC) within only 48–72 h of in vitro culture (fast-DC). Mature fast-DC are as effective as mature standard-DC (generated in 7–10 days of in vitro culture) in priming and propagation of antigen-specific T-cell responses. The use of fast-DC not only reduces labor and supply cost, as well as workload and time, but also increases the DC yield from Mo, which may facilitate DC-based immunotherapy for cancer patients. Detailed protocols for generation, pulsing with different antigen sources, and transduction with adenoviral vector of Mo-derived mature fast-DC as well as using of fast-DC for priming and propagation of antigen-specific cytotoxic T-cell effectors will be described here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bender A et al (1996) Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 196:121–135
Jonuleit H et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135–3142
Thurner B et al (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1–15
Feuerstein B et al (2000) A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 245:15–29
Bohnenkamp HR, Noll T (2003) Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application. Cytotechnology 42:121–131
Dauer M et al (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 170:4069–4076
Obermaier B et al (2003) Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proced Online 5:197–203
Ramadan G et al (2004) Generation of Aspergillus- and CMV-specific T-cell responses using autologous fast DC. Cytotherapy 6:223–234
Dauer M et al (2005) FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J Immunol Methods 302:145–155
Ramadan G et al (2005) Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. Clin Exp Immunol 139:257–267
Ramadan G et al (2005) Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen. Clin Exp Immunol 140:81–91
Ramadan G (2011) Generation of functional monocyte-derived fast dendritic cells suitable for clinical application in the absence of interleukin-6. Cytotechnology 63:513–521
Emtage PC et al (2003) Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J Immunother 26:97–106
Xu S et al (2003) Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 171:2251–2261
Keever-Taylor CA et al (2001) Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol Blood Marrow Transplant 7:247–256
Ramadan G (2008) Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes. Egypt J Immunol 15:145–157
Ramadan G (2012) In vitro expansion of human γδ and CD56+ T-cells by Aspergillus-antigen loaded fast dendritic cells in the presence of exogenous interleukin-12. Immunopharmacol Immunotoxicol 34:309–316
Ramadan G (2004) The proliferative response of T cells to Aspergillus antigen requires prior presentation on dendritic cells. Egypt J Immunol 11:47–58
Zhu F et al (2008) Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses. Clin Exp Immunol 151:284–296
Acknowledgements
This work was supported in part by awards from the Medical College of Wisconsin Cancer Center, the Boynton Fund of the Greater Milwaukee Foundation, the Rebecca Slye Fund, and the North-west Mutual Liberty Foundation. The author thanks Dr. Carolyn A. Keever-Taylor (Director) and all staff of BMT Processing Laboratories (Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital, Milwaukee, WI, USA) for technical support and discussion. The author also thanks Dr. Gordon R. Sandford, Dr. William H Burns, Candace Krepel (Medical College of Wisconsin), and Dr. Viswanath P. Kurup (VA Medical Center, Milwaukee, WI, USA) for kindly providing the adenoviral vector, CMV Strain AD169, Aspergillus fumigatus conidia, Aspergillus fumigatus crude extract antigen, respectively.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Ramadan, G. (2014). Fast Monocyte-Derived Dendritic Cell-Based Immunotherapy. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols